The psychoactive agent MDMA (3,4-methylenedioxymethamphetamine) delivered in an outpatient psychiatric clinic with intensive psychotherapy is safe and may enhance the benefits of psychotherapy in the treatment of posttraumatic stress disorder (PTSD), concluded a phase 2 study published in Lancet Psychiatry.
Twenty-six military veterans and first responders with chronic PTSD were randomly assigned to psychotherapy plus 1 of 3 MDMA dose groups: 30 mg (active control), 75 mg, or 125 mg. Participants received 3 initial 90-minute psychotherapy sessions to prepare for the MDMA experience. The agent was administered in two 8-hour sessions of specially adapted psychotherapy sessions about 1 month apart. Each session was followed by an overnight stay onsite, 7 days of telephone contact, and three 90-minute psychotherapy sessions.
Slomski A. MDMA-Assisted Psychotherapy for PTSD. JAMA. 2018;319(24):2470. doi:10.1001/jama.2018.8168
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: